Horizon Investments LLC Has $1.81 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Horizon Investments LLC grew its holdings in Zoetis Inc. (NYSE:ZTS) by 2.9% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 11,157 shares of the company’s stock after buying an additional 314 shares during the quarter. Horizon Investments LLC’s holdings in Zoetis were worth $1,812,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in the business. Mission Wealth Management LP raised its stake in shares of Zoetis by 2.0% in the 4th quarter. Mission Wealth Management LP now owns 2,938 shares of the company’s stock valued at $479,000 after buying an additional 59 shares in the last quarter. Hancock Whitney Corp raised its stake in shares of Zoetis by 0.3% in the 3rd quarter. Hancock Whitney Corp now owns 18,569 shares of the company’s stock valued at $3,628,000 after buying an additional 61 shares in the last quarter. Strategy Asset Managers LLC raised its stake in shares of Zoetis by 3.5% in the 3rd quarter. Strategy Asset Managers LLC now owns 1,822 shares of the company’s stock valued at $356,000 after buying an additional 62 shares in the last quarter. VeraBank N.A. raised its stake in shares of Zoetis by 4.1% in the 4th quarter. VeraBank N.A. now owns 1,562 shares of the company’s stock valued at $254,000 after buying an additional 62 shares in the last quarter. Finally, Procyon Advisors LLC raised its stake in shares of Zoetis by 1.4% in the 4th quarter. Procyon Advisors LLC now owns 4,712 shares of the company’s stock valued at $768,000 after buying an additional 63 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Insider Transactions at Zoetis

In other news, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the sale, the director now owns 11,245 shares in the company, valued at $1,868,244.30. The trade was a 9.71 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the sale, the executive vice president now owns 15,781 shares of the company’s stock, valued at approximately $2,682,770. This represents a 2.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,862 shares of company stock worth $312,254 in the last quarter. 0.16% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ZTS. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Leerink Partners began coverage on shares of Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price on the stock. StockNews.com raised shares of Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. Morgan Stanley lowered their target price on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. Finally, UBS Group began coverage on shares of Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price on the stock. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $215.90.

Zoetis Trading Down 0.5 %

ZTS opened at $164.28 on Wednesday. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The stock has a market capitalization of $73.56 billion, a PE ratio of 30.03, a PEG ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $200.33. The firm has a 50-day moving average price of $166.83 and a two-hundred day moving average price of $175.84.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The company had revenue of $2.32 billion during the quarter, compared to analysts’ expectations of $2.30 billion. As a group, equities analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be given a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.22%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio is 36.56%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.